Pushing back bond payments
Faron Pharmaceuticals Ltd (LSE:FARN) has agreed with its convertible bondholder to defer €1.4 million of scheduled repayments that were due in early October. The question this article examines is why the clinical-stage drug developer has chosen to delay these payments, and how the decision fits with its cash position and the expensive trial it plans to start. The company's own explanation centres on limiting dilution for shareholders.
The company and its drug candidate
Faron is a clinical-stage biopharmaceutical company developing bexmarilimab, an antibody targeting the Clever-1 receptor, for blood cancers. Its shares trade on AIM in London under the code FARN and on Nasdaq First North in Helsinki under FARON. Dr Juho Jalkanen is chief executive. The company reported no Revenue in the first half of 2026 and funds its clinical development through a combination of share issues and debt.
Its lead programme is the BEXMAB study, a phase 1/2 trial combining bexmarilimab with azacitidine in acute myeloid leukaemia and myelodysplastic syndrome (MDS). According to its half-year report, matured data presented in June 2026 showed a median duration of complete remission of 16.1 months in treatment-naive higher-risk MDS. Faron plans a randomised phase 2b study, BEXERA, in frontline higher-risk MDS, expected to begin in the second half of 2026 with 90 participants across 35 sites in the US, Europe and the UK.
The 30 September agreement
On 30 September 2026, Faron announced that it and Heights Capital Management had mutually agreed to defer Amortisation payments on convertible bonds that were due on 2 October 2026. The deferred amounts total €1.4 million: €840,000 on the first Tranche and €560,000 on the second. The first-tranche amount is now due on 2 April 2028 and the second-tranche amount on 2 December 2028, in line with the final maturities of those tranches, whose principal amounts are €15 million and €10 million respectively. Interest payments of €63,000 and €98,000 were deferred to 2 December 2026.
The company said the deferral would "limit near-term dilution for our shareholders and gives us additional flexibility." Convertible Bond amortisation can often be settled in shares, so deferring payments may reduce near-term share issuance, although the announcement did not give conversion terms.
Dilution has also arisen in other ways. On 17 September 2026, Faron issued 153,917 additional warrants to lender IPF Fund II at an exercise price of €0.4316, a step it linked to the earlier amortisation of the Heights bonds. That took IPF's total to 3,795,384 warrants, about 1.67% of issued share capital.
Financial position
Faron's half-year report for the six months to 30 June 2026, published on 26 August, showed an operating loss of €11.1 million, compared with €11.8 million a year earlier, and a net loss of €8.5 million against €19.3 million. Cash was €32.0 million, up from €13.5 million, after the company raised €40.1 million gross from a share issue in April 2026, with €7.2 million of transaction costs. Net Assets were €11.6 million, compared with negative €16.7 million a year earlier, and borrowings related to convertible bonds totalled €17.8 million.
Risks and points to watch
Drug development carries high clinical and regulatory risk, and bexmarilimab remains investigational. The BEXERA trial will add costs, and further fundraising may be needed, which could dilute shareholders. Deferring bond payments does not remove the obligation; it moves the deferred repayments into 2028, when the bonds also mature. Investors may watch the start of BEXERA, further BEXMAB data and any additional changes to financing arrangements.
Conclusion
Faron deferred €1.4 million of convertible bond payments to reduce near-term dilution and keep financial flexibility as it prepares for its phase 2b trial. The move eases pressure in the short term, but the company's future still depends on clinical results and continued access to funding.






Please wait processing your request...